Press Releases

Summary of the comments on the Elkart Electrophysiology System

"…The Elkart System is modern, effective, and very competitive with other systems currently available in the West. It appears to be reasonably easy to use, the tracings are excellent, and there are multiple options in terms of data storage. Many physicians performing "routine" EPS would find the present system quite sufficient, particularly if staffing is relatively limited. This would be particularly true if the device is priced very competitively…"

John D. Fisher, MD, FACC, FESC
Director, Arrhythmia Services
Professor of Medicine
Albert Einstein College of Medicine

Recently we had a pleasure to welcome Dr. John D. Fisher, M.D., F.A.C.C., director of arrhythmia services of Montefiore Medical Center, Bronx, New York to Tomsk. Dr. Fisher arrived to Russia for a week’s visit at request of ELECTROPULSE company. During his visit Dr. Fisher observed several operations at the Tomsk Research Institute of Cardiology and evaluated ELECTROPULSE’s medical equipment that was used in the course of these operations. “…I did not discover any disadvantages of the devices I have seen so far. This equipment is quite comparable with what we are currently using in the U.S. I think the ELKART lab can be very competitive in the U.S. market…” commented Dr. Fisher in his interviews to local mass media. He also noticed that ELECTROPULSE was the first and only Russian company that submitted Premarket Approval application for its product to FDA. Besides that Dr. Fisher accepted an invitation to participate in the 5^th International Slavic Congress on Pacing and Cardiac Electrophysiology that took place in St. Petersburg, February 7-9, 2002 and delivered a talk during one of the scientific sessions.

Soon we will provide Dr. Fisher’s assessment of the ELKART lab for your information.

We are glad to announce that on 30th of April, 2001 ElectroPulse Corporation Inc. (our American division) operating in Boston, Mass has submitted a premarket approval application ("PMA") to the United States Food and Drug Administration for the ELKART EP Lab Kit, a computer-controlled EP/RFCA diagnostic kit intended for use in intracardiac electrophysiological (EP) studies, high frequency low-amplitude myocardium signals recording, endocardiac diagnostic and therapeutic pacing, and radiofrequency catheter ablation (RFCA) of cardiac conducting pathways. Our file No. 2375/011.

(from left to right) V.M. Shevelev; Rostislav S. Karpov, member of Academy of Medical Sciences of Russian Federation, director of Tomsk Research Institute of Cardiology; Yuriy L. Shevtchenko, minister of public health of Russian Federation; Prof. Sergey V. Popov, MD, head of heart rhythm abnormalities department of Tomsk Research Institute of Cardiology; Alexander A. Kostrikin, director of ELECTROPULSE Medical Industries Ltd.

(from left to right) Prof. Sergey V. Popov, MD, head of heart rhythm abnormalities department of Tomsk Research Institute of Cardiology; Prof. Mark E. Josephson, MD, director of Harvard-Thorndike Electrophysiology Institute and Arrhythmia; Alexander A. Kostrikin, director of ELECTROPULSE Medical Industries Ltd.